CGTX News and Press, Cognition Therapeutics Inc.

PURCHASE, N.Y., April 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the 25th Annual Needham...

Advancing Zervimesine (CT1812) towards late-stage trials for  dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  ...

2026-03-26 10:46:00 ET Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call March 26, 2026 8:30 AM EDT... Read the full article on Seeking Alpha For further details see: Cognition Therapeutics, Inc. (CGTX) Q4 2025 Earnings Call Transcript

2026-03-26 07:34:14 ET More on Cognition Therapeutics Seeking Alpha’s Quant Rating on Cognition Therapeutics Historical earnings data for Cognition Therapeutics Financial information for Cognition Therapeutics Read the full article on Seeking Alpha ...

-Advancing zervimesine clinical development in DLB psychosis –  - Meeting with FDA Division of Psychiatry expected by mid-2026 - - Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CG...

PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for t...

2026-03-20 16:57:02 ET More on the markets The 'Monetary Truman Show' Is Over: The Fed Is No Longer In Control Dow Jones And U.S. Stock Market Outlook - U.S. Yields Explode, Dampening Investor Sentiment Chair Powell Is Not Leaving And Other Observations Marke...

Jasper Therapeutics Inc. (JSPR) is expected to report $-0.79 for Q4 2025 MetaVia Inc. (MTVA) is expected to report $-2.06 for Q4 2025 York Space Systems Inc. (YSS) is expected to report $-0.17 for Q4 2025 Intellicheck Inc. (IDN) is expected to report $0.02 for Q4 2025 Scholastic C...

Cognition Therapeutics Inc. (CGTX) is expected to report $-0.06 for Q4 2025

2026-03-18 18:38:05 ET Cognition Therapeutics, Inc. (CGTX) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 1.93%. The average open to low on the day of earnings was -8.04%. The average o...